Survey of 200 rheumatologists shows BMY’s Orencia is outdueling Actemra, Simponi, and Cimzia in the RA second-line biologic setting (i.e. the third-line setting overall, following methotrexate in the first line and Humira, Enbrel, or Remicade in the second line):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.